TFFP vs. RDHL, MEIP, UBX, APRE, NNVC, TXMD, APM, ACST, LSTA, and FBRX
Should you be buying TFF Pharmaceuticals stock or one of its competitors? The main competitors of TFF Pharmaceuticals include RedHill Biopharma (RDHL), MEI Pharma (MEIP), Unity Biotechnology (UBX), Aprea Therapeutics (APRE), NanoViricides (NNVC), TherapeuticsMD (TXMD), Aptorum Group (APM), Acasti Pharma (ACST), Lisata Therapeutics (LSTA), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical preparations" industry.
TFF Pharmaceuticals (NASDAQ:TFFP) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.
15.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are owned by institutional investors. 4.5% of TFF Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of RedHill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, RedHill Biopharma had 1 more articles in the media than TFF Pharmaceuticals. MarketBeat recorded 4 mentions for RedHill Biopharma and 3 mentions for TFF Pharmaceuticals. RedHill Biopharma's average media sentiment score of 1.40 beat TFF Pharmaceuticals' score of 1.25 indicating that RedHill Biopharma is being referred to more favorably in the news media.
RedHill Biopharma received 360 more outperform votes than TFF Pharmaceuticals when rated by MarketBeat users. Likewise, 68.76% of users gave RedHill Biopharma an outperform vote while only 67.68% of users gave TFF Pharmaceuticals an outperform vote.
TFF Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500.
TFF Pharmaceuticals presently has a consensus price target of $44.00, indicating a potential upside of 1,890.95%. Given TFF Pharmaceuticals' higher probable upside, equities research analysts clearly believe TFF Pharmaceuticals is more favorable than RedHill Biopharma.
RedHill Biopharma has higher revenue and earnings than TFF Pharmaceuticals.
RedHill Biopharma has a net margin of 0.00% compared to TFF Pharmaceuticals' net margin of -2,251.52%. RedHill Biopharma's return on equity of 0.00% beat TFF Pharmaceuticals' return on equity.
Summary
RedHill Biopharma beats TFF Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get TFF Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFFP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TFF Pharmaceuticals Competitors List
Related Companies and Tools
